Microtome market seen reaching $0.36 billion by 2030

The global microtome market reached $0.26 billion in 2025 and is projected to grow to $0.36 billion by 2030, according to a new report from The Business Research Company. Demand tied to cancer diagnostics, histopathology testing, automation and digital pathology is driving the outlook, with North America leading the market in 2025.

Why it matters: - Microtomes are central to tissue sectioning for microscopic analysis, which supports disease diagnosis and medical research. - Rising cancer cases and broader use of precision diagnostics are expanding demand for the instruments. - The market’s growth signals more spending on laboratory modernization, automation and pathology workflows.

What happened: - The Business Research Company released a report on the global microtome market covering 2026-2035. - The report values the market at $0.26 billion in 2025. - The market is forecast to reach $0.28 billion in 2026. - The report projects the market will hit $0.36 billion by 2030. - The report links the outlook to a 6.3% CAGR from 2025 to 2026 and 6.6% CAGR through 2030. - A free sample of the report is available. - A full version of the report is also available.

The details: - A microtome is a laboratory instrument used to cut thin biological tissue sections for microscopic examination. - The report cites growing demand for histopathology testing, advances in cancer diagnostics, academic research, microscopy use and laboratory modernization as key near-term drivers. - Longer-term growth is tied to digital pathology, automated laboratory workflows, precision diagnostics, increased research funding and hospital laboratory upgrades. - Emerging trends include automated tissue sectioning, high-precision microtomy, cryostat-assisted sectioning, improved blade safety technologies and compact laboratory instruments. - The report also highlights North America as the largest regional market in 2025. - Other regions covered include Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report says its 2026 editions include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and key technology and future-trend analysis.

Between the lines: - The forecast reflects how diagnostic demand is shifting from manual lab processes toward higher-throughput and more standardized workflows. - Cancer care remains a major demand engine because tissue analysis depends on accurate sectioning before pathologists can classify tumors and assess progression. - North America’s lead likely reflects deeper healthcare infrastructure and faster adoption of advanced medical technologies. - The report’s added analytics suggest buyers want more decision tools, not just market estimates.

What's next: - Microtome demand is expected to grow as labs adopt digital pathology and automation more widely. - Hospital laboratories and research institutions are likely to remain key end markets for upgraded tissue-sectioning systems. - The report expects broader regional contribution as healthcare systems modernize and technology access expands.